CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Dr Michael Pollak
O. Harold Warwick Prize co-recipient in 2012
Dr Michael Pollak’s research focuses on cancer metabolism and the connection between insulin and insulin-like growth factor activity in relation to cancer development. In 1998, Dr Pollak published a landmark paper which showed that the risk of prostate cancer varies with the level of insulin-like growth factors (IGFs). This and his further work have described the influence of insulin and IGFs on certain cancers and have made Dr Pollak a world leader in this area.
He is active in both clinical and translational research and has used his research findings to initiate clinical trials of novel agents related to growth factor targets. He has several ongoing projects to develop new cancer therapies and cancer prevention strategies. His research interests are broad, and include fundamental work in cellular molecular biology, translational science, prevention research and clinical studies.
Dr Pollak is the director of the division of cancer prevention of the department of oncology and medicine at McGill University and is a medical oncologist at the Jewish General Hospital. He has published more than 300 research papers and collaborates with leading cancer research groups worldwide.
Dr Pollak is a sought after speaker and presenter at major cancer research meetings and participates on many national and international committees. His strength as a cancer research ambassador relates to his ability to link the human challenges of cancer care to the research community.